Jul 10 2008 - Power3 Medical Products, Inc. (OTCBB:PWRM) announced the filing of a US Patent application for the diagnosis of multiple forms of Alzheimer’s disease by monitoring a panel of protein biomarkers in human blood serum. This latest filing further extends the reach of the recently filed US Utility Patent Application that identified 47 protein biomarkers useful in the early diagnosis of Alzheimer’s disease. Because early signs of AD are often hard to distinguish from normal signs of aging, most patients are not diagnosed until neuronal damage is extensive. A diagnostic test that will allow physicians to diagnose AD patients earlier and with greater accuracy would enable those patients to begin drug treatment when it could be most effective. More than 18 million people world-wide have Alzheimer’s disease. This figure is projected to nearly double to 34 million by 2025... Power3 Medical Products' Press Release -
